中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
3期
167-168
,共2页
肺心病心力衰竭%低分子肝素%厄贝沙坦
肺心病心力衰竭%低分子肝素%阨貝沙坦
폐심병심력쇠갈%저분자간소%액패사탄
Cardiopulmonary disease%Low molecular heparin%Irbesartan
目的：探究肺心病心力衰竭患者的治疗方法和效果。方法选取2013年3月～2014年5月收治的76例肺心病心力衰竭患者进行治疗，随机分组，实验组39例患者采用低分子肝素和厄贝沙坦的联合治疗，对照组37例患者选择常规治疗，观察患者身体的恢复情况。结果实验组治疗总有效率为94.87%，对照组治疗总有效率为83.78%，两组患者的治疗效果差异显著，有统计学意义（P<0.05）。结论肺心病心力衰竭患者采用低分子肝素和厄贝沙坦的联合治疗，可明显缓解患者的身体症状。
目的：探究肺心病心力衰竭患者的治療方法和效果。方法選取2013年3月～2014年5月收治的76例肺心病心力衰竭患者進行治療，隨機分組，實驗組39例患者採用低分子肝素和阨貝沙坦的聯閤治療，對照組37例患者選擇常規治療，觀察患者身體的恢複情況。結果實驗組治療總有效率為94.87%，對照組治療總有效率為83.78%，兩組患者的治療效果差異顯著，有統計學意義（P<0.05）。結論肺心病心力衰竭患者採用低分子肝素和阨貝沙坦的聯閤治療，可明顯緩解患者的身體癥狀。
목적：탐구폐심병심력쇠갈환자적치료방법화효과。방법선취2013년3월～2014년5월수치적76례폐심병심력쇠갈환자진행치료，수궤분조，실험조39례환자채용저분자간소화액패사탄적연합치료，대조조37례환자선택상규치료，관찰환자신체적회복정황。결과실험조치료총유효솔위94.87%，대조조치료총유효솔위83.78%，량조환자적치료효과차이현저，유통계학의의（P<0.05）。결론폐심병심력쇠갈환자채용저분자간소화액패사탄적연합치료，가명현완해환자적신체증상。
Objective The treatment methods and treatment effect on patients with cardiopulmonary disease is to be analyzed. Methods Choose 76 patients with cardiopulmonary disease who are treated in hospital from March 2013 to May 2014 and separate them into study group and control group at random,39 patients in study group are given combination treatment of low molecular heparin and Irbesartan medicine treatment,while 37 patients in control group are given conventional treatment, and then observe patients’ recovery state. Results The efficiency rate in study group is up to 94.87%,and in control group it is 83.78%;there is a great differential between two groups,which has the statistic value(P<0.05).Conclusions Combination treatment of low molecular heparin and Irbesartan medicine treatment is effective to relieve symptoms of patients with cardiopulmonary disease greatly, which is worthy of being applied and promoted.
